To include your compound in the COVID-19 Resource Center, submit it here.

AbbVie planning risankizumab submissions in psoriasis

AbbVie Inc. (NYSE:ABBV) plans to submit worldwide regulatory applications in 2018 for risankizumab (BI 655066) to treat moderate to severe plaque psoriasis after the candidate met the co-primary and all ranked secondary endpoints in a fourth Phase III trial for the indication.

In the first portion of

Read the full 465 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers